After exactly 8 years,
postmenopausal women with hormone-sensitive breast cancer who
received (Arimidex), generically known as anastrazole, had a
lower risk of recurrence than women taking tamoxifen,
investigators reported at the annual meeting of the San Antonio
Breast Cancer Symposium.

More: - From the site